Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.53M | -12.77M | 3.25M | -25.30M | -33.77M |
| Total Depreciation and Amortization | 118.00K | 151.00K | 176.00K | 176.00K | 125.00K |
| Total Amortization of Deferred Charges | 495.00K | 402.00K | 402.00K | 401.00K | 401.00K |
| Total Other Non-Cash Items | 2.23M | 2.69M | 1.96M | 177.00K | -19.00K |
| Change in Net Operating Assets | -4.55M | -14.31M | 11.20M | -19.24M | 11.77M |
| Cash from Operations | -17.23M | -23.83M | 16.99M | -43.78M | -21.49M |
| Capital Expenditure | -- | -- | -- | -- | -474.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.83M | 52.13M | 15.48M | 40.58M | 54.17M |
| Cash from Investing | 4.83M | 52.13M | 15.48M | 40.58M | 53.70M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.00M | 0.00 | -45.00M | -- | -- |
| Issuance of Common Stock | 73.00K | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -572.00K | -25.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -78.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -1.00K |
| Cash from Financing | -2.93M | 0.00 | -45.00M | -572.00K | -104.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.33M | 28.29M | -12.52M | -3.77M | 32.11M |